ImmunGene Regains Antibody-Interferon Fusion Product Candidates from Valor Biotherapeutics

CAMARILLO, Calif., May 2, 2017 /PRNewswire/ -- ImmunGene, Inc. today announced that it has regained development rights to three of its antibody-interferon fusion product candidates, IGN001, IGN002, and IGN003, from Valor Biotherapeutics, LLC (Valor). ImmunGene's lead product candidate, IGN002, is presently in a phase 1 clinical study for people with relapsed/refractory non-Hodgkin lymphoma; IGN001 and IGN003 are in preclinical studies.   

"The consolidation of these assets allows ImmunGene to have complete development control of these product candidates," said Sanjay D. Khare, Ph.D., President & CEO of ImmunGene.  "We believe our Focused Interferon Therapeutics (FIT) technology, a platform comprised of highly potent cytokines genetically engineered with monoclonal antibodies, has the potential to improve the treatment of certain cancers by targeting the delivery of interferon to the tumor microenvironment."

As part of this agreement, Valor, a joint venture between ImmunGene and G-Con LLC (aka Caliber Biotherapeutics LLC), is investing in ImmunGene to support the development of ImmunGene's product candidates based on the FIT-technology platform. "We look forward to continuing our relationship with ImmunGene to advance the company's FIT product candidates against a wide range of oncologic targets," said James Graham, general manager of Caliber.

About ImmunGene

ImmunGene is a privately held biotechnology company focused on the development of monoclonal antibody-based therapies for the treatment of cancer. ImmunGene has several programs at various stages of the development. The Company's lead product candidate, IGN002, is a new class of biotherapeutics genetically engineered by fusing two clinically validated anti-cancer drugs—an anti-CD20 antibody and interferon alpha, a protein that plays a critical role in regulating the immune system. ImmunGene has partnered the IGN002 program with The Leukemia & Lymphoma Society on the pre-clinical development, manufacturing, and initial proof-of-concept clinical study. In addition, the company has developed proprietary antibody-cytokine fusion technology comprised of highly potent cytokines by genetically engineered with monoclonal antibodies. ImmunGene has an exclusive license on the antibody-cytokine fusion protein technology developed by Sherie Morrison, Ph.D. at UCLA. More information can be found at: www.immungene.com.

SOURCE ImmunGene, Inc.

Related Links

http://www.immungene.com